Vendor Risk Management for Clinical Decision Support Vendors: HIPAA Compliance Guide

Clinical decision support (CDS) tools can influence care while handling sensitive patient information. Before onboarding a vendor, you need to understand what data the product uses, how its recommendations are generated, and what happens when the vendor or its subcontractors experience a security or service disruption.

Use a documented, risk-based review that connects your organization’s electronic protected health information risk analysis to vendor selection, contract terms, technical safeguards, and ongoing monitoring. HIPAA does not prescribe a single vendor questionnaire or review schedule; the assessment should reflect your environment and the risks identified.

How to assess clinical decision support vendors before onboarding

Start by defining the product’s intended clinical use and the work the vendor will perform. Identify which CDS functions users will access, which care workflows they affect, and whether the tool provides information, recommendations, predictions, or alerts.

Map the data flow before providing access. Document what information enters the system, whether it includes protected health information (PHI) or electronic PHI (ePHI), where it is stored or processed, who can access it, and whether the vendor uses it for analytics, product improvement, or model training. Include integrations, support tools, logs, backups, and any downstream service providers.

Evaluate the risks to confidentiality, integrity, and availability—not just whether a vendor has a security policy. Ask how its controls address your organization’s identified risks, and record remaining risks, mitigations, owners, and approval decisions. HHS explains that Security Rule risk analysis covers potential risks and vulnerabilities to ePHI and should inform the safeguards selected. See HHS guidance on risk analysis.

• Request a current security overview, risk-management materials, incident-response summary, and relevant independent assessment reports, if available.
• Review access management, encryption practices, logging, vulnerability management, backup and recovery, workforce training, and subcontractor oversight.
• Ask how the vendor will support your clinical safety, privacy, and continuity requirements, including during outages or product changes.
• Confirm whether the vendor will sign a business associate agreement (BAA) when required and whether its subcontractors that handle ePHI are covered by appropriate agreements.

HIPAA does not expressly require a business associate to provide its customer with security documentation or permit customer audits. You can request evidence and audit rights through contract terms or other agreements as part of your risk-management process. HHS explains this distinction in its guidance for cloud service providers. A private audit report can inform your review, but it does not by itself establish that your organization or the vendor is “HIPAA certified.”

When does a clinical decision support vendor qualify as a business associate?

A vendor is generally a business associate when it performs a service or function for a covered entity that involves creating, receiving, maintaining, or transmitting PHI on the entity’s behalf. For example, a CDS vendor that processes patient records to generate recommendations for a healthcare provider will commonly be acting as a business associate. A vendor’s label for its product or its claim that it is “HIPAA compliant” does not decide the issue; assess what the vendor actually does and what information it handles.

A vendor that does not handle PHI on your behalf may not be a business associate for that service. Assess whether information is genuinely de-identified before sharing it, and consider whether support access, telemetry, or integrations could expose PHI. HHS describes the definition and explains that business associates also include subcontractors that handle PHI for another business associate in its Business Associates FAQ.

When a BAA is required, put it in place before disclosing PHI to the vendor. The agreement should describe permitted uses and disclosures, require appropriate safeguards, address incident and breach reporting, place applicable obligations on business associate subcontractors, and establish what happens to PHI when the relationship ends. HHS summarizes required contract provisions in its business associate contract guidance.

Which HIPAA safeguards should vendor risk assessments verify?

The HIPAA Security Rule requires regulated entities to use reasonable and appropriate administrative, physical, and technical safeguards to protect ePHI. The specific controls you should expect from a vendor depend on the risks, the service, and your contractual arrangements. Review the HHS Security Rule summary and connect the vendor’s controls to your organization’s risk analysis.

• Administrative safeguards: Review security responsibilities, workforce access approvals and training, risk management, incident handling, contingency planning, and how the vendor oversees subcontractors.
• Physical safeguards: Ask how facilities, devices, and media containing ePHI are protected, including controls for equipment use, storage, disposal, and physical access.
• Technical safeguards: Verify unique user identification, role-based permissions, audit logging, integrity protections, and transmission security. Check that least-privilege access controls limit vendor staff and service accounts to the access needed for their tasks.

Ask how the vendor protects ePHI in transit and at rest, but do not treat a particular technical measure as a universal HIPAA checklist item. For example, encryption specifications are “addressable” under the Security Rule: that does not make them optional by default. The regulated entity must assess whether the measure is reasonable and appropriate and, if it is not, document that determination and implement an equivalent alternative when reasonable and appropriate. HHS discusses this risk-based approach in its risk analysis guidance.

Request evidence proportionate to the risk, such as security policies, assessment summaries, penetration-test summaries, remediation tracking, and backup or recovery test results. Review the scope and date of each document, any exceptions, and whether it covers the specific service and systems you will use. A certificate or assessment report is evidence to evaluate—not a substitute for your own risk analysis.

How to monitor vendors and reassess changes or incidents

Vendor risk management should continue after onboarding. Track contract renewals, open remediation items, service availability, security notifications, and changes to the product or its data flows. HHS says risk analysis is ongoing and that organizations should update and document security measures as needed; the Security Rule does not set one universal reassessment interval. See HHS guidance on periodic review and updates.

Set a review cadence based on the vendor’s access, clinical impact, and risk profile. An organization may choose annual reviews for higher-risk vendors, but annual review is a risk-management practice—not a universal federal HIPAA deadline. Reassess promptly when a material change could alter risk, such as a new subcontractor, expanded data use, major software release, change in hosting or access, security incident, or change to the CDS model or intended use.

Document what changed, whether the existing safeguards and BAA still fit, what additional evidence or remediation is needed, and who approved continued use. If you become aware of a material pattern of noncompliance with the BAA, HHS guidance describes the obligation to take reasonable steps to cure the issue or end the violation and, if unsuccessful, terminate the agreement when feasible.

How to evaluate clinical decision support software regulatory status

HIPAA status and FDA status are separate questions. HIPAA concerns how PHI is protected and used; FDA oversight depends on the product’s functions and intended use. A CDS product may have some functions that are non-device software and other functions that are medical-device functions, so assess the functions rather than relying on a broad product label.

Ask the vendor for its intended-use statement, product description, user and patient populations, input requirements, and explanation of how clinicians can review the basis for recommendations. FDA’s current Clinical Decision Support Software guidance, issued in January 2026, explains the statutory criteria for certain non-device CDS functions and clarifies that other device-software policies may still apply. The guidance is FDA’s current thinking; evaluate the vendor’s position against the actual product and seek regulatory advice where needed.

For non-device CDS criteria, the nature of the inputs and whether a healthcare professional can independently review the basis for a recommendation are important considerations. FDA provides additional information about that review in its clinical decision support policy navigator. Ask the vendor to explain its regulatory rationale and identify any device functions, clearances, authorizations, or submission status it represents as applicable; do not assume that a general marketing claim establishes regulatory status.

What AI-specific controls should vendor reviews address?

If the CDS tool uses machine learning or generative AI, extend your review to AI model integrity and data governance. Determine what data the model receives, whether prompts or outputs may contain PHI, how long data is retained, and whether it is used to train or improve models. Confirm that the vendor contract restricts PHI use and disclosure to permitted purposes, including by relevant subcontractors.

Ask how the vendor validates performance for the intended population and workflow, monitors for errors or drift, documents model versions, and tests material updates before deployment. Review how the vendor communicates limitations, uncertainty, and the basis for outputs so clinicians can apply appropriate judgment. For generative systems, also ask how the vendor handles fabricated outputs, unsafe recommendations, prompt or data leakage, and human review.

These are risk-management questions, not a separate list of AI controls expressly mandated by HIPAA. They can help you assess the clinical and information-security risks of a specific product. The NIST AI Risk Management Framework offers a voluntary approach organized around governing, mapping, measuring, and managing AI risks across a system’s lifecycle.

How to coordinate vendor incident response and recovery

Before launch, align the vendor’s incident process with your own security, privacy, clinical operations, and legal teams. The BAA must require a business associate to report security incidents it becomes aware of, and breach notification obligations apply when a breach of unsecured PHI occurs. HHS states that a business associate must notify the covered entity without unreasonable delay and no later than 60 days after discovery of a breach; that outside limit is not necessarily an appropriate operational reporting deadline for your contract. See the HHS Breach Notification Rule.

Set contract terms that specify how quickly the vendor must notify you, which contact channels to use, and what information it must provide. Ask the plan to cover:

• Who leads response, who is notified, and how the vendor coordinates with your organization and any subcontractors.
• How the vendor contains the incident, preserves relevant evidence, investigates its scope, and provides updates.
• How the vendor identifies affected systems, records, and individuals, and supports your assessment and required notifications.
• How the service will be restored, how backups and recovery are tested, and what clinical downtime procedures users should follow.
• How the vendor will report root causes, corrective actions, and changes intended to prevent recurrence.

For CDS systems, recovery planning should also address how clinicians can access an approved downtime workflow, whether recommendations need to be revalidated after a disruption, and how users will be alerted to known service or model issues. A documented risk-based assessment, clear BAA terms, appropriately scoped safeguards, and ongoing monitoring give you a practical foundation for managing vendor risk while protecting ePHI and supporting safe clinical use.

FAQs

When must a clinical decision support vendor sign a business associate agreement?

When the vendor performs a service for a covered entity that involves creating, receiving, maintaining, or transmitting PHI on the entity’s behalf, a BAA is generally required. Put the agreement in place before disclosing PHI to the vendor. Assess the actual service and data flows, including subcontractors, rather than relying only on the vendor’s description of its product.

What security evidence should a healthcare organization request from a vendor?

Request evidence suited to the service’s risk, such as security policies, risk-assessment or independent-audit summaries, penetration-test summaries, remediation information, access-control and logging descriptions, incident-response procedures, and backup or recovery test results. HIPAA does not expressly require a business associate to provide these documents or permit customer audits, so address evidence and audit rights in the contract if you need them.

How often should clinical decision support vendors be reassessed?

HIPAA does not specify a universal vendor reassessment schedule. Set a risk-based cadence and reassess when material changes or incidents could affect your organization’s risk, such as new data uses, subcontractors, integrations, model updates, or security events. An annual review can be an organizational choice, not a universal federal requirement.

What should a vendor incident response plan cover?

It should define reporting contacts and timelines, response roles, containment and investigation, evidence preservation, the scope of affected systems and PHI, coordination with subcontractors, support for required notifications, service restoration, clinical downtime procedures, and corrective actions. Align the vendor’s plan with your BAA and internal response process.